SCHEMBL5660460

SCHEMBL5660460

CC(Cc1cccc(C(=N)N)c1)C(=O)NCC(=O)NCCc1c[nH]c2ccccc12

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 9/20 0.65
MEN1 O00255 8/20 0.65
MAPT P10636 3/20 0.65
TSHR P16473 2/20 0.65
KDM4E B2RXH2 1/20 0.65
ALDH1A1 P00352 1/20 0.65
CYP3A4 P08684 1/20 0.65
ALOX15 P16050 1/20 0.65
MAPK1 P28482 1/20 0.65
HSD17B10 Q99714 1/20 0.65
TDP1 Q9NUW8 1/20 0.65
CDK4 P11802 1/20 0.48
CCND1 P24385 1/20 0.48
AANAT Q16613 1/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
ITGB3 P05106 1/20 0.48
ITGB1 P05556 1/20 0.48
ITGAV P06756 1/20 0.48
ITGA5 P08648 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5659324 0.91 KMT2A (0.63) KMT2AMEN1MAPTTSHRKDM4E
SCHEMBL5660699 0.89 MEN1 (0.58) KMT2AMEN1MAPTTSHRKDM4E
SCHEMBL5660295 0.86 MEN1 (0.58) KMT2AMEN1MAPTTSHRKDM4E
SCHEMBL5660862 0.86 MEN1 (0.55) KMT2AMEN1MAPTTSHRKDM4E
SCHEMBL5662044 0.85 MEN1 (0.56) KMT2AMEN1MAPTTSHRKDM4E
SCHEMBL5661106 0.85 MEN1 (0.54) KMT2AMEN1MAPTTSHRKDM4E
SCHEMBL5658486 0.85 KMT2A (0.57) KMT2AMEN1MAPTTSHRKDM4E
SCHEMBL5659163 0.85 KMT2A (0.58) KMT2AMEN1MAPTTSHRKDM4E
Hydrochloric Acid SCHEMBL6370935 0.84 MEN1 (0.53) KMT2AMEN1MAPTTSHRKDM4E
Hydrochloric Acid SCHEMBL6365463 0.83 MEN1 (0.51) KMT2AMEN1MAPTTSHRKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7256194-B2 Prevent thrombosis; anticholesterol agents; cardiovascular disorders; anticancer agents MORPHOCHEM (DE) 2007-08-14 US disclosed
EP-1370526-B1 DIAMIDES WHICH INHIBIT TRYPTASE AND FACTOR XA ACTIVITY MORPHOCHEM AG KOMB CHEMIE (DE) 2006-05-24 EP disclosed
US-20040082547-A1 Novel compounds that inhibit factor xa activity MORPHOCHEM (DE) 2004-04-29 US disclosed
EP-1370526-A1 DIAMIDES WHICH INHIBIT TRYPTASE AND FACTOR XA ACTIVITY Morphochem Aktiengesellschaft Für Kombinatorische Chemie (DE) 2003-12-17 EP disclosed
WO-2002068390-A1 DIAMIDES WHICH INHIBIT TRYPTASE AND FACTOR XA ACTIVITY Morphochem Aktiengesellschaft für kombinatorische Chemie (DE) 2002-09-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082547-A1 Novel compounds that inhibit factor xa activity F11, TFPI, SERPINC1 KMT2A 3724/4885MEN1 625/4885MAPT 4190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.